Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT03735589I/IINewly diagnosed stage II-IV ovarian cancer that responded to first-line platinum therapyA Phase I/IIa Safety and Immunologic Efficacy Trial of Intraperitoneal Induction of CTLs Combined With Alpha-Dendritic Cell Vaccine for Primary Ovarian CancerNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Alpha-DC1 vaccineImmune response against tumor-associated antigensClinical Trials
Autologous nCTLsAutologous Natural Killer Cell-like nCTLs, autologous natural killer-like cytotoxic lymphocytes, autologous aDC1-induced CTLsAnti-tumor immune responseClinical Trials
NCT03839524IHigh grade serous ovarian cancer with complete response after first-line platinum therapy (w/ banked tumor tissue)A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.AZ, FL, MNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TG4050MyVAC, Modified Vaccinia Ankara (MVA) personalized vaccineImmune response against tumor-associated antigensClinical Trials
NCT04367675IOvarian cancer with no evidence of disease after first-line treatmentPhase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 MutationsContact research study staffView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INO-5401WT1/PSMA/hTERT-encoding plasmid DNA INO-5401Immune response against cancer expressing hTERT, PMSA or WT1Clinical Trials
INO-9012DNA plasmid encoding interleukin-12 INO-9012IL-12 receptor agonistClinical Trials
NCT03054909IStage III/IV ovarian cancer with stable disease or better after first-line IV/IP cisplatin and paclitaxel therapy (maintenance)QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal CancerMNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
N-803ALT-803, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex N-803IL-2/IL-15 receptor beta-common gamma chain agonistClinical Trials

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.